Extracellular vesicles (EVs) are membrane-bound vesicles released into the extracellular space by almost all types of cells. EVs can cross the physiological barriers, and a variety of biological fluids are enriched in them. EVs are a heterogeneous population of vesicles, including exosomes, microvesicles, and apoptotic bodies. The different subpopulations of vesicles can be differentiated by size and origin, in which exosomes (~100 nm and from endocytic origin) are the most studied so far. EVs have essential roles in cell-to-cell communication and are critical modulators of immune response under normal and pathological conditions. Pregnancy is a unique situation of immune-modulation in which the maternal immune system protects the fetus from allogenic rejection and maintains the immunosurveillance. The placenta is a vital organ that performs a multitude of functions to support the pregnancy. The EVs derived from the human placenta have crucial roles in regulating the maternal immune response for successful pregnancy outcome. Placenta-derived vesicles perform a myriad of functions like suppression of immune reaction to the developing fetus and establishment and maintenance of a systemic inflammatory response to combat infectious intruders. A fine-tuning of these mechanisms is quintessential for successful completion of pregnancy and healthy outcome for mother and fetus. Dysregulation in the mechanisms mentioned above can lead to several pregnancy disorders. In this review, we summarize the current literature regarding the critical roles played by the EVs in immunomodulation during pregnancy with particular attention to the placenta-derived exosomes.
Introduction
Pregnancy is a unique situation of immunomodulation in which the maternal immune system adapts itself with the semi-allogenic fetus and maintains its efficiency to fight against the external pathogens. This has been achieved by expressing a unique array of antigen presenting molecules at the maternal-fetal interface and alteration of cytokine profile from Th1 to Th2, thereby skewing the immunity from cell-mediated to adaptive, with increased numbers of regulatory T cells [47, 62] .
It has been proposed that factors released from placenta can mediate the immunological adaptations in pregnancy [74] . Hormones, cytokines, and protein factors derived from placenta mediate this [17] . The shedding of microparticles, referred to as Btrophoblast debri^is a classical feature of pregnancy and these microparticles are reported to affect the systemic inflammatory response in mother [1, 15] . The particles shed from the placenta are predominantly EVs, which are membrane-bound vesicles released from the cell into the extracellular space and immense literature implicates them as important mediators of intercellular communication (reviewed in [53] ).
Depending upon the morphology and the biosynthetic mechanism responsible for their origin, there are basically three types of EVs, namely apoptotic bodies, microvesicles (MVs), and exosomes [20] . Apoptotic bodies originate from the apoptotic bleb and are approximately 800 nm to 5 μm in size, whereas MVs which are 50 to 1000 nm in diameter originate from the outward budding of the plasma membrane. Exosomes are 40-120 nm in diameter, originating from the endosomal pathway in the cell and secreted into the extracellular space [59] . A proper discrimination between the different populations of EVs is challenging due to lack of better knowledge regarding the precise mechanisms of their biogenesis and secretion as well as the limitations of existing methods to isolate pure populations of a single vesicle type.
EVs are important modulators of immune response and play diverse roles in the immune system by interacting with various immune cells and transferring information between them [90] . The secretion of EVs from placenta is therefore considered to be a potential mechanism by which maternal immune system is modulated [58] . In this review, we aim to summarize the recent literature of EVs in pregnancy, most importantly exosomes derived from placenta and their vital roles in immunological adaptations in pregnancy.
EVs as critical players in immune-modulation
Formerly, EVs were considered as mere Bgarbage bags^to get rid of waste products from the cell. The first report of EVs as messenger vehicles came when [72] described that MHC Class II molecules are enriched in the late endosomal compartments of B cells and is secreted via exosomes eliciting T cell response. Following this, [100] reported the release of exosomes from the dendritic cells modulating anti-tumor response in murine models. Currently, substantial literature unveils the myriad of roles played by these endosomal vesicles in diverse aspects of immune response such as antigen presentation via MHC-peptide complexes or bacterial or tumor antigens; immune-suppression by ligand-receptor interaction or transfer of immune-modulatory proteins and non-coding RNAs between cells, thereby changing the phenotype of the recipient cells (reviewed in [18] ).
Apart from exosomes, other EV populations like MVs are also involved in eliciting immune response. MVs derived from immune cells were studied for their role in promoting immune response in bacterial infection [34] as well as in mediating the survival and proliferation of other immune cells [26] . Interestingly, MVs released from placenta as well as maternal immune cells are reported to be key players in activating leucocytes [52, 82] as well as maintaining the competency of maternal immune system to fight against external invading organisms for successful pregnancy outcome [31, 63] . While studying the EVs and their implications on physiological systems, exosomes are versatile due to its endosomal origin and ability to selectively package the molecular cargo [98] , with immense body of literature delineating its potential roles in intercellular communication (reviewed in [20, 89] ).
Exosomes-new paradigm for intercellular communication
Intercellular communication is critical for the growth and development of organisms and is a major player in mediating various physiological and pathological events in the body. Since long time, the purview of intercellular communication involved cell signaling mediated by soluble protein factors like hormones, cytokines, and chemokines in paracrine and autocrine manner, cell-to-cell contact, and the formation of specialized gap junctions and tunneling nanotubes mediating this (reviewed in [13] ). The knowledge of exosomes as cell-to-cell communicator opened new pathways for understanding cell signaling and currently identified as a novel and efficient way of intercellular communication.
Exosomes are formed from the intra-luminal vesicles (ILVs) encapsulated inside the multi-vesicular bodies (MVBs) formed during endosomal maturation. MVBs and ILVs are formed by the inward invagination of the late endosomal membranes sequestering specific molecular cargo that are sorted into the lumen of the ILVs (reviewed in [89] ). A highly conserved group of protein complex named exosome sorting complex required for transport (ESCRT) helps in membrane remodeling, formation of MVBs and ILVs, and sorting of proteins into the ILVs. Different sub-complexes of the ESCRT machinery like ESCRT-0, I, II, and III works in a coordinated manner to promote vesicle budding and recruits the ubiquitinated proteins into the ILVs. Common exosome markers ALIX and TSG101 are integral part of the ESCRT machinery [11, 19] . An ESCRT-independent mechanism involving invagination of the ceramide-rich micro domains of the endosomal membrane, organized by tetraspanins like CD9, CD63, and CD81 and heat shock proteins, is also described [55, 84, 95] . Interestingly, exosomes are enriched in specific set of RNAs and the incorporation of RNAs into the ILVs is mediated by RNA loading proteins (reviewed in [98] ). The heterogeneous ribonucleoprotein A2B1 (hnRNPA2B1) has been implicated in the sorting of miRNAs into the ILVs [97] . The MVBs are trafficked across the cytoskeletal framework and docked to the plasma membrane by the RAB GTPase family of proteins. Several different RABs are involved in trafficking MVBs-containing ILVs of different maturation stages and proteins belonging to the soluble NSF attachment protein receptor (SNARE) complex mediate the fusion of MVBs with the plasma membrane. The existence of disparate mechanisms of exosome biogenesis and secretion explains the coexistence of heterogeneous populations of MVBs within the cells and different MVBs giving rise to different sub-populations of exosomes (reviewed in [42] ) (Fig. 1) .
Exosomes are enriched in cytosolic and membrane-associated proteins, nucleic acids including mRNAs, non-coding RNAs (most importantly miRNAs), small fragments of DNA and lipids. The molecular cargo of exosomes represents their cell of origin and these potential biological signals are conveyed to cells located proximally and distally without the requirement for cell-to-cell contact. Exosomes can permeate through different biological barriers like the endothelial barrier [4] and blood-brain barrier [2] and gain access to various biological fluids [5, 45] . The targeting of exosome to specific recipient cells involve the presence of receptors on the surface of exosome and recipient cell, followed by classical receptor-ligand interaction. In certain modes of signaling, this receptor-ligand interaction is sufficient in activating the downstream signaling pathways influencing the recipient cell function [7, 81] . In other situations, this interaction promotes the internalization of exosomes by recipient cells using different mechanisms like phagocytosis, clathrin-mediated endocytosis, caveolin-dependent endocytosis, micropinocytosis, and lipid raft-mediated uptake (reviewed in [64] ). Also, direct fusion of exosomal membrane with the cell membrane and delivering their contents inside the cell has been reported [61, 69] .
Exosome signaling pathways are associated with several important aspects of immune-regulation including immune activation and immune-suppression [18] . Pregnancy is a unique state of immune-modulation in which the maternal immune system transiently tolerates the paternal antigens of the semi-allogenic fetus, meanwhile protecting the body against external pathogens [62] . EVs including exosomes play significant roles in modulating the maternal immunity for successful pregnancy.
Pregnancy and immune-modulation
Immune-tolerance to the developing fetus is a distinctive feature of normal healthy pregnancy and several factors like the anatomical barrier between the mother and fetus, immaturity ESCRT-dependent and -independent mechanisms are involved in the biogenesis of exosomes. In the target cell, exosome mediate downstream signaling by different methods: (1) receptor-ligand interaction, (2) uptake by phagocytosis/ lipid raftmediated uptake, (3) endocytosis by clathrin/ caveolin-coated pits, and (4) direct fusion of the exosomal membrane and release of content. Synctiotrophoblast also releases microvesicles (100 nm-1 μm), formed by the direct budding from the cell membrane, syncytial nuclear aggregates (20-500 μm) with aggregates of aging nuclei, and apoptotic bodies (1-4 μm) from cells undergoing apoptosis of the fetal immune system, and immune-suppressive state of maternal system have been attributed to this [12] . But, recent literature reveals that distinct immunological adaptations characterize different stages of gestation and synchronize the maternal-fetal tolerance with the systemic immune response [62] . The immunological junction between the mother and the fetus is composed of the maternal decidual cells that develop from the endometrium and the fetal trophoblast cells with three distinct sub-populations, namely the cytotrophoblasts, multi-nucleated synctiotrophoblasts (STBs), and the invasive extra-villous trophoblasts (EVTs). The maternal immune cells at the feto-maternal interface are composed of 60-70% natural killer (NK) cells, 20-30% monocytes/macrophages, 10-15% T lymphocytes, and 1% dendritic cells (DCs) with sparse B cell population [77] .
Trophoblast cells are one of the rare cells in the human body that is devoid of specific subsets of human leucocytic antigens (HLAs) which help in promoting the immune-tolerance of mother to fetal allograft. STBs and villous cytotrophoblasts lack all the MHC Class I and MHC Class II molecules, whereas the invasive EVTs lack the HLA-A, HLA-B antigens, and the MHC Class II antigens but express a unique array of MHC Class I products, namely HLA-C, HLA-E, HLA-F, and HLA-G [6] . This unique repertoire of HLA antigens in the trophoblast cells selectively expresses the paternal antigens and regulates their recognition by the innate immune system and T cells. Hence, the lack of HLA-A and HLA-B molecules by trophoblasts restricts the presentation of fetal antigens to the maternal immune cells and the expression of HLA-C, HLA-E, HLA-G, and HLA-F by EVTs interacts with specific ligand on the NK cells and downregulates their cytotoxic function [60, 92] .
Additionally, the maternal immunosurveillence against infectious intruders is maintained by a deviation in the cytokine profile from cell-mediated immunity, identified as Th1 to humoral immunity, identified as Th2 (reviewed in [70] ). The main cytokines of the Th1 immunity are tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and interleukin (IL)-2, IL-6, IL-8, IL-12, and IL-15 and those in the Th2 immune response are TNF-β, IL-4, IL-5, IL-9, IL-10, and IL-13 [16] . Pregnancy hormones play a major role in mediating this bias towards the Th2 profile by increasing the production of Th2 cytokines at the maternal-fetal interface [49, 80] .
As aforementioned, pregnancy is not a single event of immune-suppression but rather a complicated scenario of immunomodulation for maintaining the efficiency of mother to eliminate the invading pathogens without damaging the fetus. [62] aligned the immunological phases of pregnancy with the stages of gestation such as (1) first trimester and early second trimester, in which there is active implantation and placentation, represent an immunological scenario of 'wound healing' and characterized by pro-inflammatory environment, (2) second trimester and early third trimester represent an immunological suppressive stage offering maternal-fetal tolerance, and (3) terminal part of third trimester characterized by revival of the pro-inflammatory condition for the expulsion of fetus and placenta. EVs play crucial roles in regulating and maintaining the maternal immune response in every stage of gestation with definitive effect on the immune signaling in normal and complicated pregnancies.
EVs in pregnancy and their effects on maternal immune system
Several studies have evaluated the concentrations and origins of circulating EVs in the maternal system and elucidated their ability to interact with the immune cells and regulate them [28, 57, 71, 82] . Remarkably, pregnancy is characterized by higher levels of circulating EVs than non-pregnant state and they progressively increase with gestational age, achieving highest concentration in the third trimester [65, 71, 79] . During early stages of pregnancy, EVs derived from endometrium, embryo, and trophoblast cells can influence the maternal immune response, whereas towards the advanced stages of gestation, the EVs released by the placenta, mainly STB-derived EVs, are the key players (reviewed in [94] ).
Four major sub-populations of EVs are derived from placenta mainly the (1) exosomes (30-100 nm), (2) MVs (100 nm-1 μm), also designated as STBMs, (3) syncytial nuclear aggregates (20-500 μm), by which cells deport aging nucleus in vesicles, and (4) apoptotic bodies (1-4 μm) (reviewed in [86] ). The deportation of STB-derived vesicles into the maternal circulation has been recognized as an integral part of the normal turn-over mechanism of the trophoblast cells but growing body of literature reveals that STB-derived vesicles interact with the maternal immune system and their alterations can be linked to adverse pregnancy outcomes (reviewed in [15] ). Apart from placental EVs, there is a vast repertoire of EVs derived from maternal immune cells like leucocytes and platelets eliciting significant impact on the immunogenic, thrombogenic, and vascular mechanisms in pregnancy [50, 51, 57] . Since the mechanism of biogenesis is different for each sub-type of EVs, their function and effect on the immune system vary between the sub-types. The exosome and non-exosome EV populations from placenta differ significantly in their molecular cargo and impart different effects on the maternal immune cells [67] . Hence, in this review, we summarize the immune-modulatory properties of EVs as two categories, firstly the immunomodulatory functions of placental exosomes and secondly immunomodulatory properties of STBMs in pregnancy.
Placental exosomes and their immunomodulatory functions in pregnancy
The exosome secretion is a potential mechanism by which placenta evades the cytotoxic effect of the maternal immune system and modulates the immune-tolerance to the fetal patern a l a n t i g e n s . M a j o r i t y o f t h e s t u d i e s f o r t h e immune-modulatory effects of exosomes in pregnancy report the immune-suppressive effects and its potential role in offering immune privilege for the developing fetus. Several immunologically relevant proteins and molecules are reported to be intimately associated with the exosome biogenesis and secreted in the bioactive form with exosomes. The expression of Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) by the placental cells has been attributed to be an important mechanism by which the local fetal tolerance is developed. FasL and TRAIL are members of the TNF superfamily, mainly expressed in the STBs of placenta and mediate apoptosis of the maternal lymphocytes at the feto-maternal interphase. Interestingly, FasL and TRAIL are expressed exclusively from MVBs originating from the endosomal compartments, whereas the apical and basal membranes of the STBs are completely devoid of them. They are secreted in the active form on the STB-derived exosomes and mediate apoptosis of T cells and activated PBMCs offering immunotolerance to fetus [25, 83] .
Furthermore, ligands activating NKG2D receptors on NK cells and cytotoxic Tcells are expressed and stored in ILVs arising from the late endosomal compartments of STBs and secreted in exosomes. These NKG2D ligands include the MHC Class I-related antigen A and B (MICA and MICB) and ULBPs which are GPI-linked glycoproteins belonging to the extended MHC Class I family. The NKG2D ligands activate the NKG2D receptor in NK cells and cytotoxic Tcells mediating apoptosis of these cells and consequent immune-suppression and local fetal tolerance [33] . The expression of these ligands on the surface of STBs is limited and the endosomal storage of immunologically active ligand has been described as an integral mechanism of ligand storage by the placental cells to mediate fetal immune-escape via exosomes.
In addition to FasL, TRAIL, and NKG2D ligands, several members of the B7 family of immune-regulatory ligands, which bind to receptors in lymphocytes and mediate immune response, are reported to co-localize with the exosome biosynthetic machinery and released in the exosomes [43, 76] . Programmed death ligand-1 (PD-L1) is a member of B7 family of immune-regulatory ligands, expressed on activated immune cells including T cells and has major function in downregulating effector T cell activity and preventing over-stimulation of the immune system [10] . Placental exosomes express PD-L1 and mediate T cell suppression by suppressing the CD3-zeta and JAK3 pathway [76] . Moreover, B7-H1 is reported to be co-localizing with CD-63 in the exosome biosynthetic pathway, and B7-H1 and B7-H3 have been identified in the exosomes derived from explant cultures of early and term placenta [43] . Further, immune-suppressant molecule HLA-G is secreted with exosomes at early stages of gestation and subsequently decreases with the progression of pregnancy [43, 96] . Another immune-suppressant molecule with potential effect on maternal system is the syncitin-1, an endogenous retroviral envelop protein enriched in trophoblast and mediating the trophoblast fusion leading to formation of STBs. Specific protein motifs in the syncitin-1 limit it expression on the plasma membrane leading to early internalization into endosomes by interaction with the TSG101 and ALIX proteins and packaged into exosomes. Syncitin-1 expressed in exosomes suppressed the production of TNF-α, IFN-γ, and CXCL-10, presumably mediating the Th1 to Th2 shift of cytokine profile in pregnancy [93] .
Interestingly, exosome signaling in the maternal immunomodulation involves not only the expression of membrane proteins and ligand-receptor interactions, but also the exosome-mediated delivery of immune-regulatory miRNAs to recipient cells. The chromosome 19 miRNA cluster (C19MC) is an imprinted primate-specific miRNA cluster consisting of 46 miRNAs and expressed exclusively in human placenta (reviewed in [22] ). The importance of C19MC for the placental physiology and maternal health is currently unknown. C19MC miRNAs, namely miR-512-3p and miR-517-3p are carried by placenta-derived exosomes and transferred viral resistance between trophoblast cells in a paracrine manner. The suppression of viral replication by these miRNAs was mediated by induction of autophagy [21] . Also, the miRNA, miR-517a-3p carried by placental exosomes when internalized by Tcells and NK cells, was identified to target the PRKG1 gene which is involved in activation of nitric oxide/cGMP signaling pathway, Downregulation of PRKG1 gene in maternal immune cells regulates their activation and proliferation via the nitric oxide/cGMP signaling pathway [38] . A further miRNA, miR-141 carried by STB-derived exosomes, suppressed T cell proliferation and mediated the maternal tolerance to fetus. miR-141 is reported to be up-regulated in pre-eclamptic placenta and involved in the pathophysiology of this condition [66] .
In contrast to the immune-suppressive role of exosomes, some reports illustrate the pro-inflammatory functions of exosomes, in the spatial and temporal modulation of immune system in pregnancy. STB-derived exosomes are reported to increase the recruitment of monocytes from the maternal system into the fetal-maternal interface and increase the release of pro-inflammatory cytokines like IL-1β, IL-6, serpin-E1, granulocyte/monocyte colony-stimulating factor, and TNF-α [8] . Fibronectin present on the exosomal membrane binds to α5β1 integrin on the surface of macrophage mediating this effect [9] . Additionally, trophoblast cells themselves are capable of mounting specific immunological response to infections by internalizing the exosomes derived from maternal macrophages by c l a t h r i n -d e p e n d e n t e n d o c y t o s i s a n d r e l e a s i n g pro-inflammatory cytokines [37] . This reveals the presence of bi-directional trafficking mechanisms by which maternal and fetal cells communicate for orchestrating the immune-regulatory events in pregnancy.
Taken together, in pregnancy immune-suppressive functions of exosomes play more pivotal roles in regulating the maternal innate and adaptive immune response compared to their pro-inflammatory effects. The immune-suppressive effects of pregnancy on many autoimmune diseases including multiple sclerosis and autoimmune encephalomyelitis have been attributed to exosome-mediated suppression of T cells [27, 99] . Regarding placenta, exosome release from live and active trophoblast cells is an integral method of signaling between the developing fetus and the maternal immune system for achieving immune-tolerance. In contrast, the release of STB-derived MVs and apoptotic bodies leads to activation of the immune system and systemic inflammatory response.
STBMs and their immunomodulatory functions in pregnancy
The STBs of placenta constitutively produce STBMs that can interact with various target cells. It has been shown that STBMs can potentially stimulate the maternal systemic inflammation by release of pro-inflammatory cytokines such as TNF-α, IL-18, IL-12, and IFN-γ from circulating leucocytes [28] . STBMs can activate monocytes in the maternal system and increase the expression of adhesion molecule CD54 inducing the release of pro-inflammatory cytokines like IL-8, IL-6, and IL-1β [56] . Additionally, STBMs in the presence of IL-8 activated maternal neutrophils to produce neutrophil extracellular traps (NETs), which are extracellular DNA containing fibrous lattices to capture extracellular bacteria [31, 32] . In addition, STBMs can affect the proliferation and apoptosis of T cells by regulating the expression of IL-2 receptor and STAT3 phosphorylation in T cells [68, 91] . The STB fusion protein, syncytin-1, is expressed on the surface of STBMs which on interaction with the maternal immune cells can augment the release of pro-inflammatory cytokines but dampen the response to LPS challenge [35] . [82] reported the ability of STBMs to release a variety of cytokines like TNF-α, macrophage inflammatory protein-1alpha (MIP-1α), IL-1α. IL-1β, IL-6, and IL-8 from maternal immune cells mainly monocytes and B cells. They reported the downregulation of cytokine IP-10 from maternal immune cells indicating the skewing towards type 2 immunity. In this study, they obtained STBMs using different methods and identified a similar cytokine profile with STMBs derived from placental perfusion and explant culture but mechanically derived STBMs exhibiting lesser stimulatory potential. The impact of different STBM preparation on T cell activity was evaluated by (Anurag Kumar [32] ) and identified that mechanically and explant culture-derived STBMs inhibited T cell proliferation and cytokine production and perfusion-derived STBMs induced T cell proliferation with IFN-γ release. Hence, the experimental design used to isolate the STBMs such as isolation of STBMs from maternal plasma/serum, placental cell culture (primary and cell lines), placental perfusion, placental explants, and mechanical derivation from placenta have significant impact on the bioactivity of these vesicles. The degree of tissue damage involved in each procedure which determines the level of tissue necrosis and thereby the quality of STBMs may be attributing these conflicting data interpretations.
Finally, STBMs are important mediators of maternal systemic inflammatory response by interacting with a variety of immune cells. The precise mechanism by which STBM induce systemic inflammatory response is being investigated in depth. An exaggerated inflammatory response has been identified in several pregnancy disorders and a dysregulation in the deportation of STMBs and apoptotic bodies has been implicated as a key feature associated with complications in pregnancy.
Immunomodulatory role of EVs in pathological pregnancies
It has been well established that the EVs play critical roles in the development and maintenance of successful pregnancy. The concentration and bioactivity of EVs were altered in diverse pregnancy complications like PE, gestational diabetes (GDM), pre-term birth (PTB), intra-uterine growth restriction (IUGR), recurrent miscarriage, and unexplained pregnancy loss [14, 39, 46, 54, 78, 88] .
PE is a severe placenta-related disorder and a potentially dangerous complication causing significant maternal and fetal mortality [73] . The pathophysiology of PE involves a wide range of clinical variants like poor placentation characterized by defects in the spiral artery remodeling leading to placental hypoxia, maternal hypertension, and proteinuria as well as maternal thrombo-inflammatory dysregulation characterized by alteration of cytokine profile and abnormal platelet activation leading to hypercoagulation [44, 73] . An enhanced production of EVs is a classical feature of PE, contributing significantly to its pathophysiology by modulating the thrombo-inflammatory pathways in placenta [30] . Intriguingly, the STBEVs production in PE is reported to be enhanced in some studies and diminished in others depending on the experimental models used to evaluate the EV population. The methods commonly used for the detection of STBEVs are enzyme-linked immunosorbent assay (ELISA) Not mentioned Placenta exosome-mediated transfer of C19MC-associated miRNAs confers viral resistance in recipient cells [99] In vivo (mice) Differential ultracentrifugation Not mentioned Serum exosomes mediate pregnancy-associated suppression of autoimmune encephalitis [38] Trophoblast cell lines Differential ultracentrifugation EM, WB for CD63, CD81, and TSG101
Placenta-associated miRNA, miR-517a-3p, targets PRKG1 gene in T cells and NK cells and modulate the immune response [76] Plasma/serum Size exclusion chromatography and ultracentrifugation EM Placental exosome expressed FasL and PD-L1 and suppressed T cell signaling [67] Primary trophoblast culture Plasma Differential and isopycnic ultracentrifugation NTA, EM, WB for CD63, syntenin-1, and TSG101
Placental exosome possesses a distinct protein profile and more potent anti-viral activity compared to other placental EVs [27] In vivo (in mice) Differential ultracentrifugation EM Circulating exosomes in pregnancy suppress T cell activation [65] Plasma/serum ExoQuick™ (System Biosciences)
NTA, WB for Hsp70, ICAM-1, CD9, CD63, CD81,and TSG101
Circulating EVs were higher in pregnant women compared to non-pregnant women. The expression of TGF-β1 and IL-10 were higher in EVs from pregnant women and enhanced the caspase-3 activity in NK cells.
[ and flow cytometry. Studies using ELISA detects vesicles of all sizes and reported an increase in STBEVs in PE, whereas flow cytometry detects particles above 300 nm and found no significant difference in placenta-derived EVs in PE. Hence, particles below 300 nm, likely to be exosomes, could be potentially contributing to this contradiction in data [29] . Also, the molecular cargo of STBEVs varies considerably in PE pregnancies with an augmented expression of tissue factor, endoglin, and fms-like tyrosine kinase (Flt-1) which are key mediators of pathological response in PE [85] . Additionally, STBEVs are reported to contribute to thrombotic abnormalities in PE by activating platelets leading to its aggregation [87] and ATP released from the activated platelets activate purinergic-mediated NLRP3-inflammasome signaling in the trophoblast cells leading to systemic inflammation and endothelial dysfunction in PE [41] . Thus, pro-coagulant EVs act as a functional link between coagulation and inflammation in PE (reviewed in [40] ). Elegant literature unveils the interaction of STBEVs with maternal immune cells resulting in a robust inflammatory response compared to healthy pregnancy [28, 37, 48] . The STBEVs activate the maternal immune cells and elevate the expression of cytokines TNF-α, IL-18, IL-1β, and IL-12p70 and dampens the IFN-γ production. These alterations in cytokine profile are potential contributors to inflammatory disorder in PE [28, 36] . STBEV-mediated exacerbated response to LPS and activation of neutrophils leading to NET formation has been reported in PE pregnancies [31, 32, 36] .
Extracellular cues like hypoxia and glucose content have significant impact on biosynthesis of EVs including exosome (reviewed in [24] ). Low oxygen concentrations increase the release of EVs from trophoblast cells with alterations in the bioactivity such as heightened release of inflammatory cytokines, namely TNF-α and IL-6 as well as dampening the cell migratory properties [48, 96] . Additionally, high glucose concentration is reported to impart similar effect by increasing exosome release from trophoblast cells and promoting the release of pro-inflammatory cytokines including IL-6 and TNF-α from endothelial cells [75] . Further, this impact of high glucose concentration in vitro has been recapitulated in vivo in GDM pregnancies [78] . A significant proportion (nearly 12-25%) of the total circulating exosomes in mother has been contributed by placental exosomes and a strong correlation between exosome release and maternal BMI has been revealed with exosomes from obese mothers releasing more IL-6, IL-8, and TNF-α from endothelial cells (HUVEC) [23] .
In contrast, PTB pregnancies exhibited a 1.8-fold lesser concentration of exosomes than full-term pregnancies followed by a greater suppression of CD3-zeta and JAK3 pathways mediating immunotolerance to growing fetus [88] . Hence, concentration as well as the bioactivity of EVs in pregnancy is a crucial mediator of cell signaling and immunomodulation in pathological conditions. In general, exosomes derived from placenta are immunosuppressive and placental non-exosomal vesicles like STBMs are inflammatory in their bioactivity. This prompted [58] to suggest an optimal ratio between STBMs and exosomes in normal pregnancy is > 1 and skewing to a higher level culminates in pathological pregnancies and other abnormalities. A summary of the studies on 
Conclusion and future perspectives
A schematic representation of the role of exosomes during pregnancy is presented in the Fig. 2 . There has been immense research interest in the elucidation of cell signaling mediated by EVs in pregnancy and evaluation of their diagnostic and therapeutic utility. But the progress in this area has been hindered by a lack of standardized protocols that can efficiently isolate and characterize pure populations of different sub-populations of EVs. Majority of studies on placental exosomes used ultracentrifugation followed by density gradient centrifugation for isolation and characterized the vesicles based on their size below 150 nm, cup-shaped morphology on electron microscopy, and presence of endosomal markers like tetraspanins, Tsg101, and ALIX, whereas large number of studies on STMBs isolated them by ultracentrifugation and evaluated their surface markers using flow cytometry or ELISA. Since these protocols enrich a vesicle sub-type and do not eliminate completely other vesicle types, this can lead to some over-lap in the biological functions reported for these vesicles. A better understanding of the biogenetic mechanism of these vesicles could aid in a precise delineation of their markers paving way for accurate interpretation of their biological functions. Growing evidences show that placental EVs can interact with a multitude of maternal immune cells and influence their function. The bioactivity of EVs on the target cells and potential effect on the maternal immune system depends on the quality of EV preparation. Several experimental designs like isolation of EVs from biological fluids, in vitro placental primary cells and cell lines, placental explants, perfusions, and mechanical derivation from placenta have been employed. The population of EVs as well as their biological activity varies considerably with the experimental model used and gives conflicting results under certain conditions. Hence, the experimental variability attributed by experimental models Fig. 2 Schematic representation of immunomodulatory effects of placental exosomes and STBMs on maternal immune system. Immunesuppressive ligands such as FasL, TRAIL, NKG2D, and PDL-1 are present on the exosomal membrane and regulate apoptosis and cytotoxicity of maternal leucocytes. Exosome mediates pro-inflammatory effect by recruitment and activation of monocytes. STBMs mediates systemic inflammatory response in pregnancy by activating the maternal leucocytes to release pro-inflammatory cytokines should be considered while interpreting the functional activity of EVs. Additionally, majority studies reported the effect of EVs by in vitro inoculation with PBMCs and analyzing the downstream effect. This does not essentially recapitulate the in vivo situation. We believe that in vivo inoculation can give a better understanding of specific targeting of EVs and their precise biological function in the body. Finally, current literature predominantly evaluates the immunomodulatory proteins in EVs, but understanding the vital roles of other EV contents like regulatory RNAs can provide further insights into this area of research.
